当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2019年, 第19卷, 第1期, 第9,15,24,71页
标题:
对冠状动脉搭桥术病人围手术期抗血小板治疗的药学服务
DOI:
10.5428/pcar20190103
作者:
1. 吴丹娜(海南省人民医院药学部 海口 570311 wudannachangchang@163.com)
2. 韩方璇(海南省人民医院药学部 海口 570311 hfx1223@163.com)
摘要:
欢迎阅读《药学服务与研究》!您是该文第 308 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 吴丹娜,韩方璇. 对冠状动脉搭桥术病人围手术期抗血小板治疗的药学服务[J]. 药学服务与研究. 2019; 19(1): 9,15,24,71.
英文著录格式 WU Danna,HAN Fangxuan. Pharmaceutical care of the patients with coronary artery bypass surgery in anti-platelet treatment during peri-operative period[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 9,15,24,71.
参考文献:
1. Barua R S,Ambrose J A.Mechanisms of coronary thrombosis in cigarette smoke exposure[J].Arterioscler Thromb Vasc Biol,2013,33(7):1460-1467.
2. Myles P S,Smith J A,Forbes A,et al.Stopping vs.continuing aspirin before coronary artery surgery[J].N Engl J Med,2016,374(8):728-737.
3. Guyatt G H,Akl E A,Crowther M,et al.Executive summary: antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):7S-47S.
4. Douketis J D,Spyropoulos A C,Spencer F A,et al.Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):e326S-e350S.
5. WU Hengchao,WANG Jian,SUN Hansong,et al.Preoperative continuation of aspirin therapy may improve perioperative saphenous venous graft patency after off-pump coronary artery bypass grafting[J].Ann Thorac Surg,2015,99(2):576-581.
6. 贾媛芳,张雪娟,郭俊杰.血栓弹力图在心血管疾病诊治中的应用进展[J].心血管病学进展,2015,36(2):207-210.
7. Kulik A,Ruel M,Jneid H,et al.Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association[J].Circulation,2015,131(10):927-964.
8. Gaubert M,Laine M,Richard T,et al.Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients[J].Int J Cardiol,2014,173(1):120-121.
9. Cherepanov V,Fortmann S D,Hyun Kim M,et al.Annual adverse event profiles after clopidogrel,prasugrel,and ticagrelor in the Food and Drug Administration Adverse Event Reporting System[J].Eur Heart J Cardiovasc Pharmacother,2018,4(2):69-71.